Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Vitamin D-binding protein controls T cell responses to vitamin D

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Kongsbak, M, von Essen, M, Levring, TB, Schjerling, P, Woetmann, A, Odum, N, Bonefeld, C & Geisler, C 2014, 'Vitamin D-binding protein controls T cell responses to vitamin D' B M C Immunology, bind 15, nr. 1, s. 35. https://doi.org/10.1186/s12865-014-0035-2

APA

Kongsbak, M., von Essen, M., Levring, T. B., Schjerling, P., Woetmann, A., Odum, N., ... Geisler, C. (2014). Vitamin D-binding protein controls T cell responses to vitamin D. B M C Immunology, 15(1), 35. https://doi.org/10.1186/s12865-014-0035-2

CBE

Kongsbak M, von Essen M, Levring TB, Schjerling P, Woetmann A, Odum N, Bonefeld C, Geisler C. 2014. Vitamin D-binding protein controls T cell responses to vitamin D. B M C Immunology. 15(1):35. https://doi.org/10.1186/s12865-014-0035-2

MLA

Vancouver

Author

Kongsbak, Martin ; von Essen, Marina ; Levring, Trine Bøegh ; Schjerling, Peter ; Woetmann, Anders ; Odum, Niels ; Bonefeld, Charlotte ; Geisler, Carsten. / Vitamin D-binding protein controls T cell responses to vitamin D. I: B M C Immunology. 2014 ; Bind 15, Nr. 1. s. 35.

Bibtex

@article{2eb7b050f2574dbba83a622513dc7f7a,
title = "Vitamin D-binding protein controls T cell responses to vitamin D",
abstract = "Background In vitro studies have shown that the active form of vitamin D3, 1¿,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation. However, the serum concentration of 1,25(OH)2D3 is far below the effective concentration of 1,25(OH)2D3 found in in vitro studies, and it has been suggested that 1,25(OH)2D3 must be produced locally from the inactive precursor 25-hydroxyvitamin D3 (25(OH)D3) to affect ongoing immune responses in vivo. Although it has been reported that activated T cells express the 25(OH)D-1¿-hydroxylase CYP27B1 that converts 25(OH)D3 to 1,25(OH)2D3, it is still controversial whether activated T cells have the capacity to produce sufficient amounts of 1,25(OH)2D3 to affect vitamin D-responsive genes. Furthermore, it is not known how the vitamin D-binding protein (DBP) found in high concentrations in serum affects T cell responses to 25(OH)D3.ResultsWe found that activated T cells express CYP27B1 and have the capacity to produce sufficient 1,25(OH)2D3 to affect vitamin D-responsive genes when cultured with physiological concentrations of 25(OH)D3 in serum-free medium. However, if the medium was supplemented with serum or purified DBP, DBP strictly inhibited the production of 1,25(OH)2D3 and 25(OH)D3-induced T cell responses. In contrast, DBP did not inhibit the effect of exogenous 1,25(OH)2D3. Actin, arachidonic acid and albumin did not affect the sequestration of 25(OH)D3 by DBP, whereas carbonylation of DBP did.ConclusionsActivated T cells express CYP27B1 and can convert 25(OH)D3 to 1,25(OH)2D3 in sufficiently high concentrations to affect vitamin D-responsive genes when cultured in serum-free medium. However, DBP sequesters 25(OH)D3 and inhibits the production of 1,25(OH)2D3 in T cells. To fully exploit the immune-regulatory potential of vitamin D, future studies of the mechanisms that enable the immune system to exploit 25(OH)D3 and convert it to 1,25(OH)2D3 in vivo are required.",
author = "Martin Kongsbak and {von Essen}, Marina and Levring, {Trine B{\o}egh} and Peter Schjerling and Anders Woetmann and Niels Odum and Charlotte Bonefeld and Carsten Geisler",
year = "2014",
month = "9",
day = "18",
doi = "10.1186/s12865-014-0035-2",
language = "English",
volume = "15",
pages = "35",
journal = "BMC Immunology",
issn = "1471-2172",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Vitamin D-binding protein controls T cell responses to vitamin D

AU - Kongsbak, Martin

AU - von Essen, Marina

AU - Levring, Trine Bøegh

AU - Schjerling, Peter

AU - Woetmann, Anders

AU - Odum, Niels

AU - Bonefeld, Charlotte

AU - Geisler, Carsten

PY - 2014/9/18

Y1 - 2014/9/18

N2 - Background In vitro studies have shown that the active form of vitamin D3, 1¿,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation. However, the serum concentration of 1,25(OH)2D3 is far below the effective concentration of 1,25(OH)2D3 found in in vitro studies, and it has been suggested that 1,25(OH)2D3 must be produced locally from the inactive precursor 25-hydroxyvitamin D3 (25(OH)D3) to affect ongoing immune responses in vivo. Although it has been reported that activated T cells express the 25(OH)D-1¿-hydroxylase CYP27B1 that converts 25(OH)D3 to 1,25(OH)2D3, it is still controversial whether activated T cells have the capacity to produce sufficient amounts of 1,25(OH)2D3 to affect vitamin D-responsive genes. Furthermore, it is not known how the vitamin D-binding protein (DBP) found in high concentrations in serum affects T cell responses to 25(OH)D3.ResultsWe found that activated T cells express CYP27B1 and have the capacity to produce sufficient 1,25(OH)2D3 to affect vitamin D-responsive genes when cultured with physiological concentrations of 25(OH)D3 in serum-free medium. However, if the medium was supplemented with serum or purified DBP, DBP strictly inhibited the production of 1,25(OH)2D3 and 25(OH)D3-induced T cell responses. In contrast, DBP did not inhibit the effect of exogenous 1,25(OH)2D3. Actin, arachidonic acid and albumin did not affect the sequestration of 25(OH)D3 by DBP, whereas carbonylation of DBP did.ConclusionsActivated T cells express CYP27B1 and can convert 25(OH)D3 to 1,25(OH)2D3 in sufficiently high concentrations to affect vitamin D-responsive genes when cultured in serum-free medium. However, DBP sequesters 25(OH)D3 and inhibits the production of 1,25(OH)2D3 in T cells. To fully exploit the immune-regulatory potential of vitamin D, future studies of the mechanisms that enable the immune system to exploit 25(OH)D3 and convert it to 1,25(OH)2D3 in vivo are required.

AB - Background In vitro studies have shown that the active form of vitamin D3, 1¿,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation. However, the serum concentration of 1,25(OH)2D3 is far below the effective concentration of 1,25(OH)2D3 found in in vitro studies, and it has been suggested that 1,25(OH)2D3 must be produced locally from the inactive precursor 25-hydroxyvitamin D3 (25(OH)D3) to affect ongoing immune responses in vivo. Although it has been reported that activated T cells express the 25(OH)D-1¿-hydroxylase CYP27B1 that converts 25(OH)D3 to 1,25(OH)2D3, it is still controversial whether activated T cells have the capacity to produce sufficient amounts of 1,25(OH)2D3 to affect vitamin D-responsive genes. Furthermore, it is not known how the vitamin D-binding protein (DBP) found in high concentrations in serum affects T cell responses to 25(OH)D3.ResultsWe found that activated T cells express CYP27B1 and have the capacity to produce sufficient 1,25(OH)2D3 to affect vitamin D-responsive genes when cultured with physiological concentrations of 25(OH)D3 in serum-free medium. However, if the medium was supplemented with serum or purified DBP, DBP strictly inhibited the production of 1,25(OH)2D3 and 25(OH)D3-induced T cell responses. In contrast, DBP did not inhibit the effect of exogenous 1,25(OH)2D3. Actin, arachidonic acid and albumin did not affect the sequestration of 25(OH)D3 by DBP, whereas carbonylation of DBP did.ConclusionsActivated T cells express CYP27B1 and can convert 25(OH)D3 to 1,25(OH)2D3 in sufficiently high concentrations to affect vitamin D-responsive genes when cultured in serum-free medium. However, DBP sequesters 25(OH)D3 and inhibits the production of 1,25(OH)2D3 in T cells. To fully exploit the immune-regulatory potential of vitamin D, future studies of the mechanisms that enable the immune system to exploit 25(OH)D3 and convert it to 1,25(OH)2D3 in vivo are required.

U2 - 10.1186/s12865-014-0035-2

DO - 10.1186/s12865-014-0035-2

M3 - Journal article

VL - 15

SP - 35

JO - BMC Immunology

JF - BMC Immunology

SN - 1471-2172

IS - 1

ER -

ID: 44829887